PriceTargets.com logo

Aptose Biosciences - APS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.32 As of 01/21/2025 01:18 PM ET
▲ +0.02 (6.67%)

This chart shows the closing price for APS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptose Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APS

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aptose Biosciences in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.32.

This chart shows the closing price for APS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Aptose Biosciences. This rating has held steady since October 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/2/2022HC WainwrightReiterated RatingBuyC$12.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
6/3/2022JonestradingReiterated RatingBuyC$5.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/23/2022JonestradingReiterated RatingBuyC$8.00
3/23/2022HC WainwrightBoost TargetBuyC$12.00
12/14/2021HC WainwrightReiterated RatingBuyC$14.00
11/17/2021Cantor FitzgeraldReiterated RatingOverweight
11/12/2021HC WainwrightReiterated RatingBuyC$14.00
10/19/2020Cantor FitzgeraldReiterated RatingOverweight
9/22/2020Alliance Global PartnersReiterated RatingBuyC$12.00
(Data available from 1/21/2020 forward)

News Sentiment Rating

1.46 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/22/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2025

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: C$0.32
Low: C$0.32
High: C$0.35

50 Day Range

MA: C$0.33
Low: C$0.24
High: C$0.55

52 Week Range

Now: C$0.32
Low: C$0.19
High: C$2.94

Volume

20,801 shs

Average Volume

25,305 shs

Market Capitalization

C$5.80 million

P/E Ratio

N/A

Dividend Yield

0.39%

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptose Biosciences?

The following Wall Street analysts have issued research reports on Aptose Biosciences in the last year:
View the latest analyst ratings for APS.

What is the current price target for Aptose Biosciences?

0 Wall Street analysts have set twelve-month price targets for Aptose Biosciences in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Aptose Biosciences in the next year.
View the latest price targets for APS.

What is the current consensus analyst rating for Aptose Biosciences?

Aptose Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APS.

What other companies compete with Aptose Biosciences?

Other companies that are similar to Aptose Biosciences include Liberty Biopharma, BriaCell Therapeutics, Devonian Health Group, Ceapro and Reunion Neuroscience. Learn More about companies similar to Aptose Biosciences.

How do I contact Aptose Biosciences' investor relations team?

Aptose Biosciences' physical mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The biotechnology company's listed phone number is +1-647-4799828. The official website for Aptose Biosciences is aptose.com. Learn More about contacing Aptose Biosciences investor relations.